Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced receiving a Refuse-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) of MOLBREEVI, …
FDA Requests Additional Data for Savara’s MOLBREEVI Application Read More LANGHORNE, PA —Savara Inc. (Nasdaq: SVRA) announced the grant of inducement awards to five new employees.
Savara Inc. Grants Equity Awards to New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company, announced its management team will host 1×1 meetings and present at the Jefferies Global Healthcare Conference on June 4, …
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of molgramostim during two poster presentations at the ATS International Conference 2025. The …
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the first quarter ending March 31, 2025, alongside significant business updates, including the submission of its Biologics …
Savara Reports Q1 2025 Financial Results and Advances Key Milestones Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven newly hired employees as a means to attract top talent. The equity awards, issued on April 9, …
Savara Inc. Announces Equity Awards for New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, alongside key updates on its MOLBREEVI program, which aims to address …
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced a strategic loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. This financing strengthens Savara’s resources …
Savara Secures $200 Million Loan Agreement with Hercules Capital Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment …
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has introduced the aPAP ClearPath Dried Blood Spot (DBS) Test in the United States, offering a groundbreaking solution for diagnosing autoimmune pulmonary alveolar proteinosis …
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease Read More